Kringle Pharma, Inc.
A research project on the application of HGF to idiopathic femoral head necrosis has been adopted for AMED project
A joint research project with Gifu University School of Medicine has been adopted by AMED’s Practical Research for Intractable Disease program, accelerating preparation for a phase 1 clinical trial of Oremerumarin Alpha (HGF protein therapeutic). Non-clinical/preclinical data gathering will be advanced, aiming to start clinical trials for the HGF therapeutic.
Key Figures
- Project title: A physician-led clinical trial of a novel HGF therapeutic for idiopathic femoral head necrosis with high risk of femoral head collapse
- Development phase: A-1 Pharmaceutical’s trial preparation (Phase 1 steps)
- Adopted project: FY2026 intractable disease practical realization project (Second Call)
AI要約
Overview of business activities
Crinkle Pharma is advancing a joint research project with the Gifu University Hospital to develop a novel treatment for idiopathic femoral head necrosis using HGF. This research project has been adopted for AMED’s FY2026 Practical Research for Intractable Diseases (Second Call) and will advance to the phase of preparing for pharmaceutical clinical trials. The research and development lead is Prof. Haruhiko Akiyama of Gifu University, and the company, as a co-research institution, will accelerate the acquisition of non-clinical data required for trial implementation.
Outlook and impact
Data collection for initiating clinical trials and advancing preclinical studies are expected to enable an early start of clinical trials for the HGF treatment for idiopathic femoral head necrosis. The currently disclosed information is limited to the project title, development phase, project lead, and AMED adoption status; there is no disclosure of financial impact, specific funding use, or revenue figures.
Crinkle Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
